<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926690</url>
  </required_header>
  <id_info>
    <org_study_id>OTS1070103</org_study_id>
    <nct_id>NCT02926690</nct_id>
  </id_info>
  <brief_title>Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoTherapy Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoTherapy Science, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167&#xD;
      administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>During Cycle1 after the first administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OTS167PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTS167PO</intervention_name>
    <description>Single arm, no competitor</description>
    <arm_group_label>OTS167PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Dose Escalation and Dose Expansion Cohorts&#xD;
&#xD;
        Patients must meet all of the following criteria to be eligible for participation in the&#xD;
        study:&#xD;
&#xD;
          1. Female patients, ≥ 18 years of age at the time of obtaining informed consent.&#xD;
&#xD;
          2. Patients with a documented (histologically- or cytologically-proven) breast cancer&#xD;
             that is locally advanced or metastatic.&#xD;
&#xD;
          3. Patients with a malignancy that is either relapsed/refractory to standard therapy or&#xD;
             for which no standard therapy is available.&#xD;
&#xD;
          4. Patients with a malignancy that is currently not amenable to surgical intervention due&#xD;
             to either medical contraindications or non-resectability of the tumor.&#xD;
&#xD;
          5. Patients with measurable or non-measurable disease according to the Response&#xD;
             Evaluation Criteria In Solid Tumor (RECIST, v1.1).&#xD;
&#xD;
          6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of&#xD;
             0 or 1 (see APPENDIX B: Performance Status Evaluation).&#xD;
&#xD;
          7. Life expectancy of greater than or equal to 3 months.&#xD;
&#xD;
          8. Resolution of all chemotherapy-related or radiation-related toxicities to Grade 1&#xD;
             severity or lower, except for stable sensory neuropathy (less than or equal to Grade&#xD;
             2).&#xD;
&#xD;
          9. Patients who are either not of childbearing potential or who agree to use a medically&#xD;
             effective method of contraception during the study and during 3 months after the last&#xD;
             dose of study drug. (See Appendix H: Forms of contraception).&#xD;
&#xD;
         10. Patients with the ability to understand and give written informed consent for&#xD;
             participation in this trial, including all evaluations and procedures as specified by&#xD;
             this protocol.&#xD;
&#xD;
        Dose expansion Cohort - TNBC&#xD;
&#xD;
          1. Patients with conditions as follows:&#xD;
&#xD;
               -  ER &lt;10%, PR &lt;10% by IHC assay; And&#xD;
&#xD;
               -  HER2 negative based on ASCO CAP guideline&#xD;
&#xD;
          2. Patients with measurable disease according to the response evaluation criteria in TNBC&#xD;
             (RECIST, v1.1)&#xD;
&#xD;
          3. Patients with measurable disease that can be easily accessed for biopsy.&#xD;
&#xD;
          4. Relapsed (recurrence or disease progression after achieving a documented clinical&#xD;
             response to first- or second-line treatment) or refractory (disease progression while&#xD;
             receiving first line or second line treatment). In the case of TNBC, prior initial&#xD;
             therapy with at least one known active regimen for TNBC including, but not limited to,&#xD;
             any combination of anthracyclines, taxanes, platinum agents, Ixabepilone, and/or&#xD;
             cyclophosphamide is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Dose Escalation and Dose Expansion Cohorts Patients meeting any of the following criteria&#xD;
        are ineligible for participation in the study.&#xD;
&#xD;
          1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) not&#xD;
             using adequate birth control see Appendix H: Forms of contraception.&#xD;
&#xD;
          2. Patients with known central nervous system (CNS) or leptomeningeal metastases not&#xD;
             controlled by prior surgery, radiotherapy or requiring corticosteroids to control&#xD;
             symptoms, or patients with symptoms suggesting CNS involvement for which treatment is&#xD;
             required.&#xD;
&#xD;
          3. Patients with primary brain tumors.&#xD;
&#xD;
          4. Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma,&#xD;
             and multiple myeloma.&#xD;
&#xD;
          5. Patients with any of the following hematologic abnormalities at baseline. (Patients&#xD;
             may have received a red blood cell product transfusion prior to study, if clinically&#xD;
             warranted.):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,500 per mm3&#xD;
&#xD;
               -  Platelet count &lt; 100,000 per mm3&#xD;
&#xD;
               -  Hemoglobin &lt; 8.0 gm/dL&#xD;
&#xD;
          6. Patients with any of the following serum chemistry abnormalities at baseline:&#xD;
&#xD;
               -  Total bilirubin ≥ 1.5 × the ULN for the institution value&#xD;
&#xD;
               -  AST or ALT ≥ 3 × the ULN for the institution value (≥ 5 × if due to hepatic&#xD;
                  involvement by tumor)&#xD;
&#xD;
               -  Creatinine ≥ 1.5 × ULN for the institution value (or a calculated creatinine&#xD;
                  clearance &lt; 60 mL/min/1.73 m2* )&#xD;
&#xD;
          7. Patients with a significant active cardiovascular disease or condition, including:&#xD;
&#xD;
               -  Congestive heart failure (CHF)requiring therapy&#xD;
&#xD;
               -  Need for antiarrhythmic medical therapy for a ventricular arrhythmia&#xD;
&#xD;
               -  Severe conduction disturbance&#xD;
&#xD;
               -  Unstable angina pectoris requiring therapy&#xD;
&#xD;
               -  QTc interval &gt; 450 msec (males) or &gt; 470 msec (females)&#xD;
&#xD;
               -  QTc interval ≤ 300 msec&#xD;
&#xD;
               -  History of congenital long QT syndrome or congenital short QT syndrome&#xD;
&#xD;
               -  LVEF &lt; 50% as measured by echocardiography or MUGA scan&#xD;
&#xD;
               -  Uncontrolled hypertension (per the Investigator's discretion)&#xD;
&#xD;
               -  Class III or IV cardiovascular disease according to the New York Heart&#xD;
                  Association's (NYHA) Functional Criteria (see APPENDIX C: New York Heart&#xD;
                  Association's Functional Criteria).&#xD;
&#xD;
               -  Myocardial infarction (MI) within 6 months prior to first study drug&#xD;
                  administration&#xD;
&#xD;
          8. Patients with a known or suspected hypersensitivity to any of the components of&#xD;
             OTS167.&#xD;
&#xD;
          9. Patients with a known history of human immunodeficiency virus (HIV) or active&#xD;
             infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).&#xD;
&#xD;
         10. Patients with any other serious/active/uncontrolled infection, any infection requiring&#xD;
             parenteral antibiotics, or unexplained fever &gt; 38ºC within 1 week prior to first study&#xD;
             drug administration.&#xD;
&#xD;
         11. Patients with inadequate recovery from any prior surgical procedure, or patients&#xD;
             having undergone any major surgical procedure within 4 weeks prior to first study drug&#xD;
             administration.&#xD;
&#xD;
         12. Patients with any other life-threatening illness, significant organ system&#xD;
             dysfunction, or clinically significant laboratory abnormality, which, in the opinion&#xD;
             of the Investigator, would either compromise the patient's safety or interfere with&#xD;
             evaluation of the safety of the study drug.&#xD;
&#xD;
         13. Patients with a psychiatric disorder or altered mental status that would preclude&#xD;
             understanding of the informed consent process and/or completion of the necessary&#xD;
             studies.&#xD;
&#xD;
         14. Patients with the inability or with foreseeable incapacity, in the opinion of the&#xD;
             Investigator, to comply with the protocol requirements.&#xD;
&#xD;
         15. Any anti-neoplastic agent or monoclonal antibody therapy for the primary malignancy&#xD;
             (standard or experimental) within 2 weeks prior to first study drug administration.&#xD;
&#xD;
         16. Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a&#xD;
             limited field of radiation for palliation within 1 week of the first dose of study&#xD;
             treatment. If acute symptoms of radiation have fully resolved, the extent and timing&#xD;
             of radiotherapy for eligibility can be discussed between Investigator and Sponsor.&#xD;
&#xD;
         17. Patients requiring surgery for the primary or metastatic primary malignancy.&#xD;
&#xD;
         18. Herbal preparations or related over the counter (OTC) preparations/supplements&#xD;
             containing herbal ingredients within 1 week prior to first study drug administration&#xD;
             and during study.&#xD;
&#xD;
         19. Systemic hormonal therapy which is not related to breast cancer treatment (standard or&#xD;
             experimental) within 1 week prior to first study drug administration and during study.&#xD;
             The following therapies are allowed:&#xD;
&#xD;
               -  Hormonal therapy (e.g., Megace) for appetite stimulation&#xD;
&#xD;
               -  Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations&#xD;
&#xD;
               -  Oral replacement glucocorticoid therapy for adrenal insufficiency&#xD;
&#xD;
               -  Low-dose maintenance steroid therapy for other conditions (excluding steroid&#xD;
                  tapers for brain edema/metastases/radiation)&#xD;
&#xD;
               -  Hormonal contraceptive therapy (for WOCBP must be combined with non-hormonal&#xD;
                  contraceptive equivalent to a double-barrier method)&#xD;
&#xD;
         20. Any other investigational treatments during study. This includes participation in any&#xD;
             medical device or therapeutic intervention clinical trials.&#xD;
&#xD;
             Dose expansion Cohort - TNBC&#xD;
&#xD;
         21. Patients with only lesions that cannot be accessed for biopsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Glynn, RN</last_name>
      <phone>203-852-3012</phone>
      <email>patricia.glynn@wchn.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Long, APRN</last_name>
      <phone>203-852-2996</phone>
      <email>Jennifer.Long@wchn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine | NewYork-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angemaël Syldor, BA</last_name>
      <phone>646-888-5103</phone>
      <email>syldora@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Ayca Gucalp, MD</last_name>
      <phone>646-888-4536</phone>
      <email>gucalpa@mskcc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charla Parker, MSN, RN</last_name>
      <phone>713-745-1042</phone>
      <email>caparker@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>OTS167</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

